SUBSCRIBE

Cost savings from the use of biosimilars in Canada

 Posted 27/03/2020

Analysis of the potential cost savings from the use of three biosimilars (filgrastim, infliximab and insulin glargine) in Canada shows that over CA$1 billion...

more
FDA to transition NDAs to BLAs Guidelines | Posted 27/03/2020
Denosumab copy biological accepted for review i... Biosimilars/News | Posted 27/03/2020
Generics outreach programmes should target high... Generics/Research | Posted 27/03/2020
Roche continues litigation in India and receive... Pharma News | Posted 27/03/2020
Celltrion/Teva launch trastuzumab biosimilar He... Biosimilars/News | Posted 27/03/2020
Clover starts phase III trial for etanercept co... Biosimilars/Research | Posted 27/03/2020
US oncologist says Medicare should not practice... Biosimilars/General | Posted 27/03/2020
Use of biosimilars for chronic inflammatory dis... Reports | Posted 20/03/2020
Positive phase I results for Qilu’s bevacizumab... Biosimilars/Research | Posted 20/03/2020
Comments criticize FDA guidance on insulin bios... Guidelines | Posted 20/03/2020
Hospira asks Federal Circuit to reconsider Safe... Policies & Legislation | Posted 20/03/2020
Celltrion launches infliximab biosimilar Remsim... Biosimilars/News | Posted 20/03/2020
PK and PD similarity between pegfilgrastim bios... Biosimilars/Research | Posted 20/03/2020
FDA and FTC collaborate to deter anti-competiti... Biosimilars/General | Posted 20/03/2020
FDA approves lung cancer and anticoagulant gene... Generics/News | Posted 20/03/2020
Arguments against Alberta’s plans to switch pat... Biosimilars/Research | Posted 13/03/2020
ST002293
Advantages and challenges of biosimilars approv... Reports | Posted 13/03/2020
Amgen starts phase III trial for aflibercept bi... Biosimilars/News | Posted 13/03/2020
FDA publishes historic drug approvals and searc... Biosimilars/General | Posted 13/03/2020
Tackling the challenge of safe automatic substi... Biosimilars/Research | Posted 13/03/2020
Pharmacopeial standards may increase generics c... Generics/Research | Posted 13/03/2020
New biosimilars partnerships from Alvotech and... Pharma News | Posted 13/03/2020
Allergan, Ironwood settle Linzess patent dispute Policies & Legislation | Posted 13/03/2020
ST002293
FDA issues new rule on definition of term ‘biol... Guidelines | Posted 06/03/2020
Biosimilars in the age of patient-centricity Biosimilars/Research | Posted 06/03/2020
FDA accepts application for Mylan’s bevacizumab... Biosimilars/News | Posted 06/03/2020
Ontario becomes third Canadian province to swit... Biosimilars/General | Posted 06/03/2020
Amgen to buy out Japanese partner Astellas Pharma News | Posted 06/03/2020
Delayed entry of buprenorphine generics cost NH... Generics/Research | Posted 06/03/2020
19646665_l
Proposed policies to maximize societal benefit... Reports | Posted 06/03/2020
China’s procurement programme cuts drug prices... Policies & Legislation | Posted 06/03/2020
FDA issues new guidance for biosimilar user fees Guidelines | Posted 28/02/2020
16704526_l
Optimizing the benefits of biosimilars for society Reports | Posted 28/02/2020
20920796_l
Positive results for Bio-Thera’s bevacizumab co... Biosimilars/Research | Posted 28/02/2020
Celltrion to build facility in China and increa... Pharma News | Posted 28/02/2020
US patent office rules in Biogen’s favour on Te... Policies & Legislation | Posted 28/02/2020
Chinese company makes copy of patented coronavi... Generics/News | Posted 28/02/2020
Survey reveals attitudes to unauthorized hepati... Generics/Research | Posted 28/02/2020
US lawmakers question FDA on complex generics a... Generics/General | Posted 28/02/2020
FDA issues draft guidance on labelling and adve... Guidelines | Posted 21/02/2020
Reasons and solutions for the high cost of insu... Biosimilars/Research | Posted 21/02/2020
Merck to create spin off for women’s health and... Pharma News | Posted 21/02/2020
Bio-Thera launches first adalimumab copy biolog... Biosimilars/News | Posted 21/02/2020
US-Mexico-Canada agreement to benefit generics... Policies & Legislation | Posted 21/02/2020
EMA recommends four new generics Generics/News | Posted 21/02/2020
Russian drug shortages at ‘crisis point’ Generics/General | Posted 21/02/2020
Mylan launches anti-cancer biosimilar in the US Biosimilars/News | Posted 21/02/2020
Joint 26th Medicines for Europe and 23rd IGBA A... Conferences | Posted 21/02/2020
FDA issues draft guidance on licensing biosimil... Guidelines | Posted 14/02/2020
more

NON-BIOLOGICAL COMPLEX DRUGS

FDA issues final guidance on liposome drug products Posted 27/04/2018

On 4 April 2018, the US Food and Drug Administration (FDA) issued a new draft...

more


FDA approves 40 mg follow-on version of glatira... Non‐Biological Complex Drugs/News | Posted 09/03/2018
Mylan launches first follow-on glatiramer aceta... Non‐Biological Complex Drugs/News | Posted 15/02/2018
Biosimilars and follow-on NBCDs for MS in Europ... Non‐Biological Complex Drugs/Research | Posted 19/01/2018
Impax announces FDA approval of follow-on sevel... Non‐Biological Complex Drugs/News | Posted 17/11/2017
FDA approves follow-on version of sevelamer Non‐Biological Complex Drugs/News | Posted 30/06/2017
Challenges in the regulation of NBCDs Non‐Biological Complex Drugs/Research | Posted 12/05/2017
Scientific and regulatory considerations for fo... Non‐Biological Complex Drugs/Research | Posted 05/05/2017
Equivalence of complex drug products Non‐Biological Complex Drugs/Reports | Posted 14/04/2017
Follow-up studies needed to ensure safety for f... Non‐Biological Complex Drugs/Research | Posted 31/03/2017
Warning letter causes delays for follow-on glat... Non‐Biological Complex Drugs/News | Posted 17/03/2017
Is the EU ready for non-biological complex drug... Non‐Biological Complex Drugs/Research | Posted 03/03/2017
Follow-on versions of glatiramer acetate in Rus... Non‐Biological Complex Drugs/News | Posted 24/02/2017
Non-biological complex drugs and pharmacopoeias Non‐Biological Complex Drugs/Research | Posted 10/02/2017
In vitro analysis of follow-on versions of seve... Non‐Biological Complex Drugs/Research | Posted 18/11/2016
Determining the bioequivalence of follow-on iro... Non‐Biological Complex Drugs/Reports | Posted 04/11/2016
FDA to set up abbreviated pathway for complex p... Non‐Biological Complex Drugs/Polices & Legislation | Posted 21/10/2016
Challenges in the assessment of ophthalmic emul... Non‐Biological Complex Drugs/Reports | Posted 07/10/2016
Cancer lab to evaluate bioequivalence of nanosi... Non‐Biological Complex Drugs/News | Posted 23/09/2016
A conference on ‘Equivalence of Complex Drug Pr... Non‐Biological Complex Drugs/News | Posted 09/09/2016
Collaboration to introduce nanotechnologies in... Non‐Biological Complex Drugs/News | Posted 26/08/2016
Iron carbohydrate follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 12/08/2016
Rigorous approach used to approve a follow-on v... Non‐Biological Complex Drugs/Research | Posted 29/07/2016
US guidelines for follow-on NBCDs Non‐Biological Complex Drugs/Guidelines | Posted 10/06/2016
Non-biological complex drugs and their follow-o... Non‐Biological Complex Drugs/Research | Posted 03/06/2016
Is a new pathway for NBCDs on the way in the US? Non‐Biological Complex Drugs/Polices & Legislation | Posted 27/05/2016
Follow-on glatiramer acetate gains European app... Non‐Biological Complex Drugs/News | Posted 13/05/2016
FDA includes follow-on versions in its new cycl... Non‐Biological Complex Drugs/Guidelines | Posted 29/04/2016
Switching between originator and follow-on iron... Non‐Biological Complex Drugs/Research | Posted 22/04/2016
Follow-on intravenous iron formulations in haem... Non‐Biological Complex Drugs/Research | Posted 01/04/2016
Glatiramoid follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 11/03/2016
FDA includes follow-on versions in its new lipo... Non‐Biological Complex Drugs/Guidelines | Posted 26/02/2016
EU guidelines for follow-on NBCDs Non‐Biological Complex Drugs/Guidelines | Posted 22/01/2016
GDUFA regulatory priorities for 2016 include co... Non‐Biological Complex Drugs/Polices & Legislation | Posted 11/12/2015
Liposomal follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 11/12/2015
Regulations for follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 13/11/2015
Status and regulatory issues surrounding follow... Non‐Biological Complex Drugs/Reports | Posted 05/11/2015
Follow-on glatiramer acetate (M356) claimed as... Non‐Biological Complex Drugs/Research | Posted 05/11/2015
EMA issues reflection paper for follow-on versi... Non‐Biological Complex Drugs/Guidelines | Posted 05/11/2015
FDA approves first follow-on version of glatira... Non‐Biological Complex Drugs/News | Posted 05/11/2015
more

Country Focus

All countries

Sign up today to receive weekly news on the latest developments in generic and biosimilar medicines!

Generics News Research General

more

Biosimilars News Research General

more

More editorial sections